Bioventix plc
(“Bioventix” or the “Company”)
Director/PDMR Shareholding
Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, was notified on 25 October 2019 of the following
transaction in its ordinary shares of 5 pence each (“Ordinary Shares”):
Director Position Ordinary Shares sold Sale price per Ordinary Share Ordinary Shares held subsequently Percentage of issued share capital held subsequently
Ian Nicholson and Persons Closely Associated Non-Executive Chairman 2,500 3,158.67p 15,500 0.3%
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities / person closely associated
a) Names Ian Nicholson (Non-Executive Chairman)
2. Reason for the Notification
a) Position/status See 1(a) above
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Bioventix plc
b) LEI 213800225MHX7LZQY108
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Ordinary shares of 5 pence (“Ordinary Shares”)
Identification code GB00B4QVDF07
b) Nature of the transaction Sale of Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
3,158.67p 2,500
d) Aggregated information: · Aggregated volume · Price See 4(c)
e) Date of the transaction 25 October 2019
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
For further information please contact:
Bioventix plc Peter Harrison Chief Executive Officer Tel: 01252 728 001
finnCap Ltd Geoff Nash/Simon Hicks Alice Lane Corporate Finance ECM Tel: 020 7220 0500
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.
The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No.
596/2014.
Copyright (c) 2019 PR Newswire Association,LLC. All Rights Reserved